clomipramine hydrochloride

• 塩酸クロミプラミン

関

clomipramine

WordNet

1. a complex consisting of an organic base in association with hydrogen chloride
2. a tricyclic antidepressant drug

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2018/02/02 11:53:45」(JST)

wiki en

[Wiki en表示]

Clomipramine

Clinical data
Trade names	Anafranil, Clomicalm, others
Synonyms	Clomimipramine; 3-Chloroimipramine; G-34586
AHFS/Drugs.com	Monograph
MedlinePlus	a697002
License data	US FDA: Clomipramine
Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	By mouth, intravenous
ATC code	N06AA04 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	~50%
Protein binding	96–98%
Metabolism	Hepatic (CYP2D6)
Metabolites	Desmethylclomipramine
Biological half-life	CMI: 19–37 hours DCMI: 54–77 hours
Excretion	Renal (51–60%) Feces (24–32%)
Identifiers
IUPAC name 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
CAS Number	303-49-1 Y
PubChem CID	2801
IUPHAR/BPS	2398
DrugBank	DB01242 Y
ChemSpider	2699 Y
UNII	NUV44L116D
KEGG	D07727 Y
ChEBI	CHEBI:47780 Y
ChEMBL	CHEMBL415 Y
ECHA InfoCard	100.005.587
Chemical and physical data
Formula	C19H23ClN2
Molar mass	314.857 g/mol
3D model (JSmol)	Interactive image
SMILES ClC1=CC(N(CCCN(C)C)C2=C(CC3)C=CC=C2)=C3C=C1
InChI InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3 Y Key:GDLIGKIOYRNHDA-UHFFFAOYSA-N Y
(verify)

Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA). It is used for the treatment of obsessive–compulsive disorder, panic disorder, major depressive disorder, and chronic pain. It may decrease the risk of suicide in those over the age of 65. It is taken by mouth.

Common side effects include dry mouth, constipation, loss of appetite, sleepiness, weight gain, sexual dysfunction, and trouble urinating. Serious side effects include an increased risk of suicidal behavior in those under the age of 25, seizures, mania, and liver problems. If stopped suddenly a withdrawal syndrome may occur with headaches, sweating, and dizziness. It is unclear if it is safe for use in pregnancy. Its mechanism of action is not entirely clear but is believed to involve increased levels of serotonin.

Clomipramine was discovered in 1964 by the Swiss drug manufacturer Ciba-Geigy. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale price in the developing world is between 0.11 and 0.21 per day as of 2014. In the United States a typical dose costs about 1.20 USD per day. It was made from imipramine.

Medical uses

Clomipramine has a number of uses in medicine including in the treatment of:

• Obsessive–compulsive disorder (OCD) which is its only U.S. FDA-labeled indication. Other regulatory agencies (such as the TGA of Australia and the MHRA of the UK) have also approved clomipramine for this indication.
• Major depressive disorder (MDD) a popular off-label use in the US. It is approved by the Australian TGA and the United Kingdom MHRA for this indication. Some have suggested the possible superior efficacy of clomipramine compared to other antidepressants in the treatment of MDD, although at the current time the evidence is insufficient to adequately substantiate this claim.
• Panic disorder with or without agoraphobia.
• Body dysmorphic disorder
• Cataplexy associated with narcolepsy. Which is a TGA and MHRA-labeled indication for clomipramine.
• Premature ejaculation
• Depersonalization disorder
• Chronic pain with or without organic disease, particularly headache of the tension type.
• Sleep paralysis, with or without narcolepsy
• Enuresis (involuntary urinating in sleep) in children. The effect may not be sustained following treatment, and alarm therapy may be more effective in both the short-term and the long-term. Combining a tricyclic (such as clomipramine) with anticholinergic medication, may be more effective for treating enuresis than the tricyclic alone.
• Trichotillomania

In a meta-analysis of various trials involving fluoxetine (Prozac), fluvoxamine (Luvox), and sertraline (Zoloft) to test their relative efficacies in treating OCD, clomipramine was found to be the most effective.

Contraindications

Contraindications include:

• Known hypersensitivity to clomipramine, or any of the excipients or cross-sensitivity to tricyclic antidepressants of the dibenzazepine group
• Recent myocardial infarction
• Any degree of heart block or other cardiac arrhythmias
• Mania
• Severe liver disease
• Narrow angle glaucoma
• Urinary retention
• It must not be given in combination or within 3 weeks before or after treatment with an monoamine oxidase inhibitor. (Moclobemide included, however clomipramine can be initiated sooner at 48 hours following discontinuation of moclobemide.)

Pregnancy and lactation

Clomipramine use during pregnancy is associated with congenital heart defects in the newborn. It is also associated with reversible withdrawal effects in the newborn. Clomipramine is also distributed in breast milk and hence nursing while taking clomipramine is advised against.

Side effects

Clomipramine has been associated with the following side effects:

Very common (>10% frequency):

• Accommodation (eye)
• Blurred vision
• Nausea
• Dry mouth
• Constipation
• Fatigue
• Weight gain
• Increased appetite
• Dizziness
• Tremor
• Headache
• Myoclonus
• Drowsiness
• Somnolence
• Restlessness
• Micturition disorder
• Sexual dysfunction (erectile dysfunction and loss of libido)
• Hyperhidrosis (profuse sweating)

Common (1–10% frequency):

• Weight loss
• Orthostatic hypotension
• Sinus tachycardia
• Clinically irrelevant ECG changes (e.g. T- and ST-wave changes) in patients of normal cardiac status
• Palpitations
• Tinnitus (hearing ringing in one's ears)
• Mydriasis (dilated pupils)
• Vomiting
• Abdominal disorders
• Diarrhoea
• Decreased appetite
• Transaminases increased
• Alkaline phosphatase increased
• Speech disorders
• Paraesthesia
• Muscle hypertonia
• Dysgeusia
• Memory impairment
• Muscular weakness
• Disturbance in attention
• Confusional state
• Disorientation
• Hallucinations (particularly in elderly patients and patients with Parkinson's disease)
• Anxiety
• Agitation
• Sleep disorders
• Mania
• Hypomania
• Aggression
• Depersonalisation
• Insomnia
• Nightmares
• Aggravation of depression
• Delirium
• Galactorrhoea (lactation that is not associated with pregnancy or breastfeeding)
• Breast enlargement
• Yawning
• Hot flush
• Dermatitis allergic (skin rash, urticaria)
• Photosensitivity reaction
• Pruritus (itching)

Uncommon (0.1–1% frequency):

• Convulsions
• Ataxia
• Arrhythmias
• Elevated blood pressure
• Activation of psychotic symptoms

Very rare (<0.01% frequency):

• Pancytopaenia — an abnormally low amount of all the different types of blood cells in the blood (including platelets, white blood cells and red blood cells).
• Leucopenia — a low white blood cell count.
• Agranulocytosis — basically a worse form of leucopaenia; a dangerously low white blood cell count which leaves one open to life-threatening infections due to the role of the white blood cells in defending the body from invaders.
• Thrombocytopenia — an abnormally low amount of platelets in the blood which are essential to clotting and hence this leads to an increased tendency to bruise and bleed, including, potentially, internally.
• Eosinophilia — an abnormally high number of eosinophils — the cells that fight off parasitic infections — in the blood.
• Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) — a potentially fatal reaction to certain medications that is due to an excessive release of antidiuretic hormone — a hormone that prevents the production of urine by increasing the reabsorption of fluids in the kidney — this results in the development of various electrolyte abnormalities (e.g. hyponatraemia [low blood sodium], hypokalaemia [low blood potassium], hypocalcaemia [low blood calcium]).
• Glaucoma
• Oedema (local or generalised)
• Alopecia (hair loss)
• Hyperpyrexia (a high fever that is above 41.5 °C)
• Hepatitis (liver swelling) with or without jaundice — the yellowing of the eyes, the skin, and mucous membranes due to impaired liver function.
• Abnormal ECG
• Anaphylactic and anaphylactoid reactions including hypotension
• Neuroleptic malignant syndrome (NMS) — a potentially fatal side effect of antidopaminergic agents such as antipsychotics, tricyclic antidepressants and antiemetics (drugs that relieve nausea and vomiting). NMS develops over a period of days or weeks and is characterised by the following symptoms:
  • Tremor
  • Muscle rigidity
  • Mental status change (such as confusion, delirium, mania, hypomania, agitation, coma, etc.)
  • Hyperthermia (high body temperature)
  • Tachycardia (high heart rate)
  • Blood pressure changes
  • Diaphoresis (sweating profusely)
  • Diarrhoea
• Alveolitis allergic (pneumonitis) with or without eosinophilia
• Purpura

• Conduction disorder (e.g. widening of QRS complex, prolonged QT interval, PQ changes, bundle-branch block, torsade de pointes, particularly in patients with hypokalaemia)

Withdrawal

Withdrawal symptoms may occur during gradual or particularly abrupt withdrawal of tricyclic antidepressant drugs. Possible symptoms include: nausea, vomiting, abdominal pain, diarrhoea, insomnia, headache, nervousness, anxiety, dizziness and worsening of psychiatric status. Differentiating between the return of the original psychiatric disorder and clomipramine withdrawal symptoms is important. Clomipramine withdrawal can be severe. Withdrawal symptoms can also occur in neonates when clomipramine is used during pregnancy. A major mechanism of withdrawal from tricyclic antidepressants is believed to be due to a rebound effect of excessive cholinergic activity due to neuroadaptations as a result of chronic inhibition of cholinergic receptors by tricyclic antidepressants. Restarting the antidepressant and slow tapering is the treatment of choice for tricyclic antidepressant withdrawal. Some withdrawal symptoms may respond to anticholinergics, such as atropine or benztropine mesylate.

Overdose

Main article: Tricyclic antidepressant overdose

Clomipramine overdose usually presents with the following symptoms:

• Signs of central nervous system depression such as:
  • stupor
  • coma
  • drowsiness
  • restlessness
  • ataxia
• Mydriasis
• Convulsions
• Enhanced reflexes
• Muscle rigidity
• Athetoid and choreoathetoid movements
• Serotonin syndrome - a condition with many of the same symptoms as neuroleptic malignant syndrome but has a significantly more rapid onset
• Cardiovascular effects including:
  • arrhythmias (including Torsades de pointes)
  • tachycardia
  • QTc interval prolongation
  • conduction disorders
  • hypotension
  • shock
  • heart failure
  • cardiac arrest
• Apnoea
• Cyanosis
• Respiratory depression
• Vomiting
• Fever
• Sweating
• Oliguria
• Anuria

There is no specific antidote for overdose and all treatment is purely supportive and symptomatic. Treatment with activated charcoal may be used to limit absorption in cases of oral overdose. Anyone suspected of overdosing on clomipramine should be hospitalised and kept under close surveillance for at least 72 hours. Clomipramine has been reported as being less toxic in overdose than most other TCAs in one meta-analysis but this may well be due to the circumstances surrounding most overdoses as clomipramine is more frequently used to treat conditions for which the rate of suicide is not particularly high such as OCD. In another meta-analysis, however, clomipramine was associated with a significant degree of toxicity in overdose.

Interactions

Clomipramine may interact with a number of different medications, including the monoamine oxidase inhibitors which include isocarboxazid, moclobemide, phenelzine, selegiline and tranylcypromine, antiarrhythmic agents (due to the effects of TCAs like clomipramine on cardiac conduction. There is also a potential pharmacokinetic interaction with quinidine due to the fact that clomipramine is metabolised by CYP2D6 in vivo), diuretics (due to the potential for hypokalaemia (low blood potassium) to develop which increases the risk for QT interval prolongation and torsades de pointes), the selective serotonin reuptake inhibitors (SSRIs; due to both potential additive serotonergic effects leading to serotonin syndrome and the potential for a pharmacokinetic interaction with the SSRIs that inhibit CYP2D6 [e.g. fluoxetine and paroxetine]) and serotonergic agents such as triptans, other tricyclic antidepressants, tramadol, etc. (due to the potential for serotonin syndrome). Its use is also advised against in those concurrently on CYP2D6 inhibitors due the potential for increased plasma levels of clomipramine and the resulting potential for CNS and cardiotoxicity.

Pharmacology

Pharmacodynamics

See also: Pharmacology of antidepressants and Tricyclic antidepressant § Binding profiles

Clomipramine (and metabolite)

Site	CMI	DMC	Species	Ref
SERT	0.14–0.28	40	Human/rat
NET	38–53.7	0.45	Human/rat
DAT	≥2,190	2,100	Human/rat
5-HT1A	≥7,000	19,000	Human/und
5-HT1B	>10,000	ND	Human
5-HT1D	>10,000	ND	Human
5-HT2A	27–35.5	130	Human/und
5-HT2B	ND	ND	ND	ND
5-HT2C	64.6	ND	Human
5-HT3	460–985	ND	Rodent
5-HT6	53.8	ND	Rat
5-HT7	127	ND	Rat
α1	3.2–38	190	Human/und
α2	525–3,200	1,800	Human/und
β	22,000	16,000	Undefined
D1	219	320	Human/und
D2	77.6–190	1,200	Human/und
D3	30–50.1	ND	Human
D4	ND	ND	ND	ND
D5	ND	ND	ND	ND
H1	13–31	450	Human/und
H2	209	ND	Human
H3	9,770	ND	Human
H4	5,750	ND	Human
mACh	37	92	Human/und
σ1	546	ND	Rat
hERG	130 (IC50)	ND	Human
Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.

Clomipramine is a reuptake inhibitor of serotonin and norepinephrine, or a serotonin–norepinephrine reuptake inhibitor (SNRI); that is, it blocks the reuptake of these neurotransmitters back into neurons by preventing them from interacting with their transporters, thereby increasing their extracellular concentrations in the synaptic cleft and resulting in increased serotonergic and noradrenergic neurotransmission. In addition, clomipramine also has antiadrenergic, antihistamine, antiserotonergic, antidopaminergic, and anticholinergic activities. It is specifically an antagonist of the α₁-adrenergic receptor, the histamine H₁ receptor, the serotonin 5-HT_2A, 5-HT_2C, 5-HT₃, 5-HT₆, and 5-HT₇ receptors, the dopamine D₁, D₂, and D₃ receptors, and the muscarinic acetylcholine receptors (M₁–M₅). Like other TCAs, clomipramine weakly blocks voltage-dependent sodium channels as well.

Although clomipramine shows around 100- to 200-fold preference in affinity for the SERT over the NET, its major active metabolite, desmethylclomipramine (norclomipramine), binds to the NET with very high affinity (K_i = 0.32 nM) and with dramatically reduced affinity for the SERT (K_i = 31.6 nM). Moreover, desmethylclomipramine circulates at concentrations that are approximately twice those of clomipramine. In accordance, occupancy of both the SERT and the NET has been shown with clomipramine administration in positron emission tomography studies with humans and non-human primates. As such, clomipramine is in fact a fairly balanced SNRI rather than only a serotonin reuptake inhibitor (SRI).

The antidepressant effects of clomipramine are thought to be due to reuptake inhibition of serotonin and norepinephrine, while serotonin reuptake inhibition only is thought to be responsible for the effectiveness of clomipramine in the treatment of OCD. Conversely, antagonism of the H₁, α₁-adrenergic, and muscarinic acetylcholine receptors is thought to contribute to its side effects. Blockade of the H₁ receptor is specifically responsible for the antihistamine effects of clomipramine and side effects like sedation and somnolence (sleepiness). Antagonism of the α₁-adrenergic receptor is thought to cause orthostatic hypotension and dizziness. Inhibition of muscarinic acetylcholine receptors is responsible for the anticholinergic side effects of clomipramine like dry mouth, constipation, urinary retention, blurred vision, and cognitive/memory impairment. In overdose, sodium channel blockade in the brain is believed to cause the coma and seizures associated with TCAs while blockade of sodium channels in the heart is considered to cause cardiac arrhythmias, cardiac arrest, and death. On the other hand, sodium channel blockade is also thought to contribute to the analgesic effects of TCAs, for instance in the treatment of neuropathic pain.

The exceptionally strong serotonin reuptake inhibition of clomipramine likely precludes the possibility of its antagonism of serotonin receptors (which it binds to with more than 100-fold lower affinity than the SERT) resulting in a net decrease in signaling by these receptors. In accordance, while serotonin receptor antagonists like cyproheptadine and chlorpromazine are effective as antidotes against serotonin syndrome, clomipramine is nonetheless capable of inducing this syndrome. In fact, while all TCAs are SRIs and serotonin receptor antagonists to varying extents, the only TCAs that are associated with serotonin syndrome are clomipramine and to a lesser extent its dechlorinated analogue imipramine, which are the two most potent SRIs of the TCAs (and in relation to this have the highest ratios of serotonin reuptake inhibition to serotonin receptor antagonism). As such, whereas other TCAs can be combined with monoamine oxidase inhibitors (with caution due to the risk of hypertensive crisis from NET inhibition; sometimes done in treatment-resistant depressives), clomipramine cannot be due to the risk of serotonin syndrome and death. Unlike the case of its serotonin receptor antagonism, orthostatic hypotension is a common side effect of clomipramine, suggesting that its blockade of the α₁-adrenergic receptor is strong enough to overcome the stimulatory effects on the α₁-adrenergic receptor of its NET inhibition.

Serotonergic activity

Comparison of SERT-active antidepressants

Medication	SERT	NET	Dosage (mg/day)	t1/2 (M) (hours)	Cp (ng/mL)	Cp / SERT ratio
Amitriptyline	4.3	34.5	100–200	16 (30)	100–250	23–58
Amoxapine	58.5	16.1	200–300	8 (30)	200–500	3.4–8.5
Butriptyline	1,360	5,100	?	?	?	?
Clomipramine	0.14–0.28	37	100–200	32 (70)	150–500	536–3,570
Desipramine	17.5	0.8	100–200	30	125–300	7.1–17
Dosulepin	8.3	45.5	150–225	25 (34)	50–200	6.0–24
Doxepin	66.7	29.4	100–200	18 (30)	150–250	2.2–3.7
Imipramine	1.4	37	100–200	12 (30)	175–300	125–214
Iprindole	1,620	1,262	?	?	?	?
Lofepramine	70.0	5.4	?	?	?	?
Nortriptyline	18.5	4.4	75–150	31	60–150	3.2–8.1
Protriptyline	19.6	1.4	15–40	80	100–250	5.1–13
Trimipramine	149	2,450	75–200	16 (30)	100–300	0.67–2.0
Citalopram	1.4	5,100	20–40	36	75–150	54–107
Escitalopram	1.1	7,840	10–20	30	40–80	36–73
Fluoxetine	0.8	244	20–40	53 (240)	100–500	125–625
Fluvoxamine	2.2	1,300	100–200	18	100–200	45–91
Paroxetine	0.1	40	20–40	17	30–100	300–1,000
Sertraline	0.3	417	100–150	23 (66)	25–50	83–167
Duloxetine	1.6	11.2	80–100	11	?	?
Milnacipran	123	200	?	?	?	?
Venlafaxine	9.1	1,060	75–225	5 (11)	?	?
The values for the SERT and NET are Ki (nM). Note that in the Cp / SERT ratio, free versus protein-bound drug concentrations are not accounted for.

SERT occupancy by SRIs at clinically approved dosages

Medication	Dosage range (mg/day)	~80% SERT occupancy (mg/day)	Ratio (dosage / 80% occupancy)
Citalopram	20–40	40	0.5–1
Escitalopram	10–20	10	1–2
Fluoxetine	20–80	20	1–4
Fluvoxamine	50–350	70	0.71–5
Paroxetine	10–60	20	0.5–3
Sertraline	25–200	50	0.5–4
Duloxetine	20–60	30	0.67–2
Venlafaxine	75–375	75	1–5
Clomipramine	50–250	10	5–25

Clomipramine is a strong SRI. Its affinity for the SERT was reported in one study using human tissues to be 0.14 nM, which is considerably higher than that of other TCAs. For example, the TCAs with the next highest affinities for the SERT in the study were imipramine, amitriptyline, and dosulepin (dothiepin), with K_i values of 1.4 nM, 4.3 nM, and 8.3 nM, respectively. In addition, clomipramine has a terminal half-life that is around twice as long as that of amitriptyline and imipramine. In spite of these differences however, clomipramine is used clinically at the same usual dosages as other serotonergic TCAs (100–200 mg/day). It achieves typical circulating concentrations that are similar in range to those of other TCAs but with an upper limit that is around twice that of amitriptyline and imipramine. For these reasons, clomipramine is the most potent SRI among the TCAs and is far stronger as an SRI than other TCAs at typical clinical dosages. In addition, clomipramine is similarly potent or even more potent as an SRI than selective serotonin reuptake inhibitors (SSRIs).

A positron emission tomography study found that a single low dose of 10 mg clomipramine to healthy volunteers resulted in 81.1% occupancy of the SERT, which was comparable to the 84.9% SERT occupancy by 50 mg fluvoxamine. In the study, single doses of 5 to 50 mg clomipramine resulted in 67.2 to 94.0% SERT occupancy while single doses of 12.5 to 50 mg fluvoxamine resulted in 28.4 to 84.9% SERT occupancy. Chronic treatment with higher doses was able to achieve up to 100.0% SERT occupancy with clomipramine and up to 93.6% SERT occupancy with fluvoxamine. Other studies have found 83% SERT occupancy with 20 mg/day paroxetine and 77% SERT occupancy with 20 mg/day citalopram. These results indicate that very low doses of clomipramine are able to substantially occupy the SERT and that clomipramine achieves higher occupancy of the SERT than SSRIs at comparable doses. Moreover, clomipramine may be able to achieve more complete occupancy of the SERT at high doses, at least relative to fluvoxamine.

If the ratios of the 80% SERT occupancy dosage and the approved clinical dosage range are calculated and compared for SSRIs, SNRIs, and clomipramine, it can be deduced that clomipramine is by far the strongest SRI used medically. The lowest approved dosage of clomipramine can be estimated to be roughly comparable in SERT occupancy to the maximum approved dosages of the strongest SSRIs and SNRIs. Because their mechanism of action was originally not known and dose-ranging studies were never conducted, first-generation antipsychotics were dramatically overdosed in patients. It has been suggested that the same may have been true for clomipramine and other TCAs.

Obsessive–compulsive disorder

Clomipramine was the first drug that was investigated for and found to be effective in the treatment of OCD. In addition, it was the first drug to be approved by the FDA in the United States for the treatment of OCD. The effectiveness of clomipramine in the treatment of OCD is far greater than that of other TCAs, which are comparatively weak SRIs; a meta-analysis found pre- versus post-treatment effect sizes of 1.55 for clomipramine relative to a range of 0.67 for imipramine and 0.11 for desipramine. In contrast to other TCAs, studies have found that clomipramine and SSRIs, which are more potent SRIs, have similar effectiveness in the treatment of OCD. However, multiple meta-analyses have found that clomipramine nonetheless retains a significant effectiveness advantage relative to SSRIs; in the same meta-analysis mentioned previously, the effect sizes of SSRIs in the treatment of OCD ranged from 0.81 for fluoxetine to 1.36 for sertraline (relative to 1.55 for clomipramine). However, the effectiveness advantage for clomipramine has not been apparent in head-to-head comparisons of clomipramine versus SSRIs for OCD. The differences in effectiveness findings could be due to differences in methodologies across non-head-to-head studies.

Relatively high doses of SRIs are needed for effectiveness in the treatment of OCD. Studies have found that high dosages of SSRIs above the normally recommended maximums are significantly more effective in OCD treatment than lower dosages (e.g., 250 to 400 mg/day sertraline versus 200 mg/day sertraline). In addition, the combination of clomipramine and SSRIs has also been found to be significantly more effective in alleviating OCD symptoms, and clomipramine is commonly used to augment SSRIs for this reason. Studies have found that intravenous clomipramine, which is associated with very high circulating concentrations of the drug and a much higher ratio of clomipramine to its metabolite desmethylclomipramine, is more effective than oral clomipramine in the treatment of OCD. There is a case report of complete remission from OCD for approximately one month following a massive overdose of fluoxetine, an SSRI with a uniquely long duration of action. Taken together, stronger serotonin reuptake inhibition has consistently been associated with greater alleviation of OCD symptoms, and since clomipramine, at the clinical dosages in which it is employed, is effectively the strongest SRI used medically (see table above), this may underlie its unique effectiveness in the treatment of OCD.

In addition to serotonin reuptake inhibition, clomipramine is also a mild but clinically significant antagonist of the dopamine D₁, D₂, and D₃ receptors at high concentrations. Addition of antipsychotics, which are potent dopamine receptor antagonists, to SSRIs, has been found to significantly augment their effectiveness in the treatment of OCD. As such, besides strong serotonin reuptake inhibition, clomipramine at high doses might also block dopamine receptors to treat OCD symptoms, and this could additionally or alternatively be involved in its possible effectiveness advantage over SSRIs.

Although clomipramine is similarly or more effective in the treatment of OCD compared to SSRIs, it is greatly inferior to them in terms of tolerability and safety due to its lack of selectivity for the SERT and promiscuous pharmacological activity. In addition, clomipramine has high toxicity in overdose and can potentially result in death, whereas death rarely, if ever, occurs with overdose of SSRIs. It is for these reasons that clomipramine, in spite of potentially superior effectiveness to SSRIs, is now rarely used as a first-line agent in the treatment of OCD, with SSRIs being used as first-line therapies instead and clomipramine generally being reserved for more severe cases.

Pharmacokinetics

The oral bioavailability of clomipramine is approximately 50%. Peak plasma concentrations occur around 2–6 hours (with an average of 4.7 hours) after taking clomipramine orally and are in the range of 56–154 ng/mL (178–489 nmol/L). Steady-state concentrations of clomipramine are around 134–532 ng/mL (426–1,690 nmol/L), with an average of 218 ng/mL (692 nmol/L), and are reached after 7 to 14 days of repeated dosing. Steady-state concentrations of the active metabolite, desmethylclomipramine, are around 230–550 ng/mL (730–1,750 nmol/L). The volume of distribution (V_d) of clomipramine is approximately 17 L/kg. It binds approximately 97–98% to plasma proteins, primarily to albumin. Clomipramine is metabolized in the liver mainly by CYP2D6. It has a terminal half-life of 32 hours, and its N-desmethyl metabolite, desmethylclomipramine, has a terminal half-life of approximately 69 hours. Clomipramine is mostly excreted in urine (60%) and feces (32%).

Chemistry

Clomipramine is a tricyclic compound, specifically a dibenzazepine, and possesses three rings fused together with a side chain attached in its chemical structure. Other dibenzazepine TCAs include imipramine, desipramine, and trimipramine. Clomipramine is a derivative of imipramine with a chlorine atom added to one of its rings and is also known as 3-chloroimipramine. It is a tertiary amine TCA, with its side chain-demethylated metabolite desmethylclomipramine being a secondary amine. Other tertiary amine TCAs include amitriptyline, imipramine, dosulepin (dothiepin), doxepin, and trimipramine. The chemical name of clomipramine is 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine and its free base form has a chemical formula of C₁₉H₂₃ClN₂ with a molecular weight of 314.857 g/mol. The drug is used commercially almost exclusively as the hydrochloride salt; the free base has been used rarely. The CAS Registry Number of the free base is 303-49-1 and of the hydrochloride is 17321-77-6.

History

Clomipramine was developed by Geigy. It was first referenced in the literature in 1961 and was patented in 1963. The drug was first approved for medical use in Europe in the treatment of depression in 1970, and was the last of the major TCAs to be marketed. In fact, clomipramine was initially considered to be a "me-too drug" by the FDA, and in relation to this, was declined licensing for depression in the United States. As such, to this day, clomipramine remains the only TCA that is available in the United States that is not approved for the treatment of depression, in spite of the fact that it is a highly effective antidepressant. Clomipramine was eventually approved in the United States for the treatment of OCD in 1989 and became available in 1990. It was the first drug to be investigated and found effective in the treatment of OCD. The first reports of benefits in OCD were in 1967, and the first double-blind, placebo-controlled clinical trial of clomipramine for OCD was conducted in 1976, with more rigorous clinical studies that solidified its effectiveness conducted in the 1980s. It remained the "gold standard" for the treatment of OCD for many years until the introduction of the SSRIs, which have since largely superseded it due to greatly improved tolerability and safety (although notably not effectiveness). Clomipramine is the only TCA that has been shown to be effective in the treatment of OCD and that is approved by the FDA for the treatment of OCD; the other TCAs failed clinical trials for this indication, likely due to insufficient serotonergic activity.

Society and culture

Generic names

Clomipramine is the English and French generic name of the drug and its INN, BAN, and DCF, while clomipramine hydrochloride is its USAN, USP, BANM, and JAN. Clomipramina is its generic name in Spanish and Italian and its DCIT, while clomipramin is its generic name in German and clomipraminum is its generic name in Latin.

Brand names

Clomipramine is marketed throughout the world mainly under the brand names Anafranil and Clomicalm for use in humans and animals, respectively.

Veterinary uses

In the U.S., clomipramine is only licensed to treat separation anxiety in dogs for which it is sold under the brand name Clomicalm. It has proven effective in the treatment of obsessive–compulsive disorders in cats and dogs. In dogs, it has also demonstrated similar efficacy to fluoxetine in treating tail chasing. In dogs some evidence suggests its efficacy in treating noise phobia.

Clomipramine has also demonstrated efficacy in treating urine spraying in cats. Various studies have been done on the effects of clomipramine on cats to reduce urine spraying/marking behavior. It has been shown to be able to reduce this behavior by up to 75% reduction of the behavior in a trial period of four weeks.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 成人における強迫性障害に対する薬物療法 pharmacotherapy for obsessive compulsive disorder in adults
• 2. 三環系抗うつ剤および四環系抗うつ剤：薬理学、投与、および副作用 tricyclic and tetracyclic drugs pharmacology administration and side effects
• 3. 小児および思春期における強迫性障害の治療 treatment of obsessive compulsive disorder in children and adolescents
• 4. フェティシズム的障害 fetishistic disorder
• 5. 失神評価における立位チルト試験 upright tilt table testing in the evaluation of syncope

English Journal

• Clomipramine trial for treatment-resistant persistent genital arousal disorder: a case series.

• Yildirim EA1, Hacioglu Yildirim M1, Carpar E2, Sarac I3.
• Journal of psychosomatic obstetrics and gynaecology.J Psychosom Obstet Gynaecol.2017 Dec;38(4):260-267. doi: 10.1080/0167482X.2017.1296427. Epub 2017 Mar 3.
• PMID 28635538

• Synthesis and 2D-QSAR studies of neolignan-based diaryl-tetrahydrofuran and -furan analogues with remarkable activity against Trypanosoma cruzi and assessment of the trypanothione reductase activity.

• Hartmann AP1, de Carvalho MR1, Bernardes LSC2, Moraes MH3, de Melo EB4, Lopes CD5, Steindel M3, da Silva JS4, Carvalho I6.
• European journal of medicinal chemistry.Eur J Med Chem.2017 Nov 10;140:187-199. doi: 10.1016/j.ejmech.2017.08.064. Epub 2017 Sep 4.
• PMID 28926763

• Buprenorphine augmentation improved symptoms of OCD, compared to placebo - Results from a randomized, double-blind and placebo-controlled clinical trial.

• Ahmadpanah M1, Reihani A1, Ghaleiha A1, Soltanian A1, Haghighi M1, Jahangard L1, Sadeghi Bahmani D2, Holsboer-Trachsler E2, Brand S3.
• Journal of psychiatric research.J Psychiatr Res.2017 Nov;94:23-28. doi: 10.1016/j.jpsychires.2017.06.004. Epub 2017 Jun 13.
• PMID 28647677

Japanese Journal

• 夜尿症児90例の臨床的検討

• 東京女子医科大学雑誌 83(E1), E205-E211, 2013-01-31
• NAID 110009559379

• 三環系抗うつ薬の大量服用後発症した急性呼吸促迫症候群の1例

• 日本集中治療医学会雑誌 18(2), 221-225, 2011
• NAID 130004514320

• In Vitro Study of the Adsorption Characteristics of Drugs(Medicinal Chemistry)

• Biological & pharmaceutical bulletin 28(5), 841-844, 2005-05-01
• NAID 10016663278

Related Links

• Clomipramine Hydrochloride (Professional Patient Advice ...

Professional guide for Clomipramine Hydrochloride. Includes: pharmacology, pharmacokinetics, contraindications, interactions, adverse reactions and more. ... Drugs.com provides accurate and independent information on more than ...

• Clomipramine Hydrochloride Monograph for Professionals ...

Clomipramine Hydrochloride reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI). ... Cautions for Clomipramine Hydrochloride Contraindications Concurrent or recent (i.e ...

Related Pictures

---

★リンクテーブル★

リンク元	「クロミプラミン」
関連記事	「hydrochloride」

「クロミプラミン」

　　[★]

英

clomipramine

同

塩酸クロミプラミン clomipramine hydrochloride

商

アナフラニール Anafranil

「hydrochloride」

　　[★] 塩酸塩、ハイドロクロライド